Leptin and obesity - The story so far and its therapeutic implications

The story so far and its therapeutic implications

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Leptin burst onto the scene in 1994 and transformed research into obesity and energy balance. Immediately, hopes were raised that this peptide, secreted by adipose tissue, might be causally related to human obesity, and that the regulatory mechanisms underlying its action might be manipulated for therapeutic benefit.

In the last 6 years, the concentrated effort of the research community, both academic and commercial, has made enormous strides towards understanding the full range of physiological effects of leptin. In the mouse, leptin deficiency (ob/ob) induces hyperphagia, massive obesity and diabetes. Administration of leptin protein reverses this phenotype and results in rapid bodyweight loss, mainly in the form of fat. Leptin also modestly reduces food intake and bodyweight in normal lean rodents on systemic administration.

Leptin is much more potent when administered directly into the cerebroventricular system of the brain. This observation, and the identification of leptin receptor expression in hypothalamic nuclei with an established regulatory function in energy homeostasis, confirms the CNS as a primary site of action of leptin. A number of leptin-sensitive, receptor-expressing hypothalamic neurons of different neurochemical phenotype have been identified, and leptin receptor mRNA and protein are widespread elsewhere in the mammalian brain. Leptin provides two forms of feedback to regulatory systems in the brain, a dynamic reflection of diurnal feeding pattern (where it may interact with satiety signals), and a basal level of secretion encoding body fat storage (a plausible lipostat). The absence of leptin is a potent signal of starvation, and in this state reduced leptin feedback regulates the activity of compensatory neuropeptide systems in the hypothalamus to drive the Voluntary hyperphagia displayed by rodents when released back to ad libitum feeding.

Despite the initial excitement over the therapeutic potential of leptin, these expectations have now begun to wane. Assessments of the value of leptin, and of potential therapies based on its activities, are now more realistic and may involve targeting of specific subpopulations of individuals, or particular weight loss strategies. This review focuses deliberately upon the possible exploitation strategies that are still patent.

Original languageEnglish
Pages (from-to)413-424
Number of pages12
JournalCNS Drugs
Volume14
Issue number6
Publication statusPublished - Dec 2000

Keywords

  • receptor messenger-RNA
  • brown adipose-tissue
  • in-situ hybridization
  • gene-expression
  • body-weight
  • OB/OB mice
  • food-intake
  • recombinant leptin
  • mouse hypothalamus
  • pancreatic-islets
  • hormones, pharmacodynamics
  • Leptin, pharmacodynamics
  • obesity
  • research and development

Cite this

@article{453c03f56697490eb5ae41dad6c3e599,
title = "Leptin and obesity - The story so far and its therapeutic implications: The story so far and its therapeutic implications",
abstract = "Leptin burst onto the scene in 1994 and transformed research into obesity and energy balance. Immediately, hopes were raised that this peptide, secreted by adipose tissue, might be causally related to human obesity, and that the regulatory mechanisms underlying its action might be manipulated for therapeutic benefit.In the last 6 years, the concentrated effort of the research community, both academic and commercial, has made enormous strides towards understanding the full range of physiological effects of leptin. In the mouse, leptin deficiency (ob/ob) induces hyperphagia, massive obesity and diabetes. Administration of leptin protein reverses this phenotype and results in rapid bodyweight loss, mainly in the form of fat. Leptin also modestly reduces food intake and bodyweight in normal lean rodents on systemic administration.Leptin is much more potent when administered directly into the cerebroventricular system of the brain. This observation, and the identification of leptin receptor expression in hypothalamic nuclei with an established regulatory function in energy homeostasis, confirms the CNS as a primary site of action of leptin. A number of leptin-sensitive, receptor-expressing hypothalamic neurons of different neurochemical phenotype have been identified, and leptin receptor mRNA and protein are widespread elsewhere in the mammalian brain. Leptin provides two forms of feedback to regulatory systems in the brain, a dynamic reflection of diurnal feeding pattern (where it may interact with satiety signals), and a basal level of secretion encoding body fat storage (a plausible lipostat). The absence of leptin is a potent signal of starvation, and in this state reduced leptin feedback regulates the activity of compensatory neuropeptide systems in the hypothalamus to drive the Voluntary hyperphagia displayed by rodents when released back to ad libitum feeding.Despite the initial excitement over the therapeutic potential of leptin, these expectations have now begun to wane. Assessments of the value of leptin, and of potential therapies based on its activities, are now more realistic and may involve targeting of specific subpopulations of individuals, or particular weight loss strategies. This review focuses deliberately upon the possible exploitation strategies that are still patent.",
keywords = "receptor messenger-RNA, brown adipose-tissue, in-situ hybridization, gene-expression, body-weight, OB/OB mice, food-intake, recombinant leptin, mouse hypothalamus, pancreatic-islets, hormones, pharmacodynamics, Leptin, pharmacodynamics, obesity, research and development",
author = "Julian Mercer and Nigel Hoggard and Morgan, {Peter John}",
year = "2000",
month = "12",
language = "English",
volume = "14",
pages = "413--424",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Leptin and obesity - The story so far and its therapeutic implications

T2 - The story so far and its therapeutic implications

AU - Mercer, Julian

AU - Hoggard, Nigel

AU - Morgan, Peter John

PY - 2000/12

Y1 - 2000/12

N2 - Leptin burst onto the scene in 1994 and transformed research into obesity and energy balance. Immediately, hopes were raised that this peptide, secreted by adipose tissue, might be causally related to human obesity, and that the regulatory mechanisms underlying its action might be manipulated for therapeutic benefit.In the last 6 years, the concentrated effort of the research community, both academic and commercial, has made enormous strides towards understanding the full range of physiological effects of leptin. In the mouse, leptin deficiency (ob/ob) induces hyperphagia, massive obesity and diabetes. Administration of leptin protein reverses this phenotype and results in rapid bodyweight loss, mainly in the form of fat. Leptin also modestly reduces food intake and bodyweight in normal lean rodents on systemic administration.Leptin is much more potent when administered directly into the cerebroventricular system of the brain. This observation, and the identification of leptin receptor expression in hypothalamic nuclei with an established regulatory function in energy homeostasis, confirms the CNS as a primary site of action of leptin. A number of leptin-sensitive, receptor-expressing hypothalamic neurons of different neurochemical phenotype have been identified, and leptin receptor mRNA and protein are widespread elsewhere in the mammalian brain. Leptin provides two forms of feedback to regulatory systems in the brain, a dynamic reflection of diurnal feeding pattern (where it may interact with satiety signals), and a basal level of secretion encoding body fat storage (a plausible lipostat). The absence of leptin is a potent signal of starvation, and in this state reduced leptin feedback regulates the activity of compensatory neuropeptide systems in the hypothalamus to drive the Voluntary hyperphagia displayed by rodents when released back to ad libitum feeding.Despite the initial excitement over the therapeutic potential of leptin, these expectations have now begun to wane. Assessments of the value of leptin, and of potential therapies based on its activities, are now more realistic and may involve targeting of specific subpopulations of individuals, or particular weight loss strategies. This review focuses deliberately upon the possible exploitation strategies that are still patent.

AB - Leptin burst onto the scene in 1994 and transformed research into obesity and energy balance. Immediately, hopes were raised that this peptide, secreted by adipose tissue, might be causally related to human obesity, and that the regulatory mechanisms underlying its action might be manipulated for therapeutic benefit.In the last 6 years, the concentrated effort of the research community, both academic and commercial, has made enormous strides towards understanding the full range of physiological effects of leptin. In the mouse, leptin deficiency (ob/ob) induces hyperphagia, massive obesity and diabetes. Administration of leptin protein reverses this phenotype and results in rapid bodyweight loss, mainly in the form of fat. Leptin also modestly reduces food intake and bodyweight in normal lean rodents on systemic administration.Leptin is much more potent when administered directly into the cerebroventricular system of the brain. This observation, and the identification of leptin receptor expression in hypothalamic nuclei with an established regulatory function in energy homeostasis, confirms the CNS as a primary site of action of leptin. A number of leptin-sensitive, receptor-expressing hypothalamic neurons of different neurochemical phenotype have been identified, and leptin receptor mRNA and protein are widespread elsewhere in the mammalian brain. Leptin provides two forms of feedback to regulatory systems in the brain, a dynamic reflection of diurnal feeding pattern (where it may interact with satiety signals), and a basal level of secretion encoding body fat storage (a plausible lipostat). The absence of leptin is a potent signal of starvation, and in this state reduced leptin feedback regulates the activity of compensatory neuropeptide systems in the hypothalamus to drive the Voluntary hyperphagia displayed by rodents when released back to ad libitum feeding.Despite the initial excitement over the therapeutic potential of leptin, these expectations have now begun to wane. Assessments of the value of leptin, and of potential therapies based on its activities, are now more realistic and may involve targeting of specific subpopulations of individuals, or particular weight loss strategies. This review focuses deliberately upon the possible exploitation strategies that are still patent.

KW - receptor messenger-RNA

KW - brown adipose-tissue

KW - in-situ hybridization

KW - gene-expression

KW - body-weight

KW - OB/OB mice

KW - food-intake

KW - recombinant leptin

KW - mouse hypothalamus

KW - pancreatic-islets

KW - hormones, pharmacodynamics

KW - Leptin, pharmacodynamics

KW - obesity

KW - research and development

M3 - Article

VL - 14

SP - 413

EP - 424

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 6

ER -